Nephrology

Chronic kidney disease-associated pruritus (CKD-aP) occurs in over two-thirds of patients undergoing haemodialysis. The aetiology of CKD-aP may be multifactorial, involving immune system and opioid dysregulation, peripheral neuropathy, and toxin deposition. CKD-aP can be extremely bothersome for some patients, affecting health-related quality of life and sleep, as well as increasing the likelihood of hospitalisation, infections, and death.

Over the past few decades, there have been important advances in cancer therapeutics, including a shift from traditional cytotoxic…

AAV is a rare and severe multisystem disease affecting the small arteries.1,2 The condition is characterised by systemic inflammation across multiple body sites including the lungs, joints, kidneys, nerves, ears, and nose.1,2 Glucocorticoids and immunosuppressants form the cornerstone of current treatment approaches.

CKD-aP necessitates a differential diagnosis to ascertain that the itching a patient is experiencing is related to…

Chronic kidney disease can result in morbidity and mortality not only due to renal dysfunction itself, but also to associated…

Kenar D. Jhaveri | Professor of Medicine and Associate Chief in the Division of Kidney Diseases and Hypertension, Hofstra/Northwell School of Medicine, Hempstead, New York, USA

The use of BVM dates back to the early 1990s when CRIT-LINE® technology (Fresenius Medical Care, Bad Homburg, Germany) was first used as a non-invasive method of measuring haematocrit changes during haemodialysis, in real time, by connection of an additional monitor to the dialysis arterial line set-up.

Imlifidase was granted a conditional marketing authorisation by the European Commission in August 2020 for “desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor.”36 This milestone launched a new era in kidney transplantation for selected patients who would previously have remained untreated.